Premium
Potential predictive markers for breast cancer aggressiveness and invasiveness
Author(s) -
Wang Wan,
Wang Qiuyue,
Gao Ling,
Gone Pengtao,
Zhang Xichen,
Man Yangao
Publication year - 2009
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.23.1_supplement.38.6
Subject(s) - breast cancer , myoepithelial cell , medicine , oncology , christian ministry , breast carcinoma , predictive value , cancer , cancer research , suppressor , pathology , immunohistochemistry , philosophy , theology
Clinical follow‐up studies have shown that only 10‐30% of untreated in situ breast carcinoma progress to invasion during patients' lifetime. None of the current approaches, however, could predict tumor invasiveness or identify the specific individuals at greater risk for invasive lesions. As myoepithelial (ME) cells are the sole source of several tumor suppressors and the disruption of ME cell layer is a pre‐requisite for tumor invasion, our recent studies compared the expression profile of tumor suppressors and the physical integrity of ME cell layers in pregnancy‐associated breast cancer (PABC) and inflammatory breast cancers (IBC), which have the highest degree of aggressiveness and invasiveness, with those of clinically idle breast cancers. Compared to their counterparts, the ME cell layers in pre‐invasive PABC and IBC have several unique properties: [1] significantly lower expression of tumor suppressors, especially WT‐1, [2] a significantly higher frequency of focal disruptions, and [3] a significantly higher infiltration of immunoreactive cells. Our studies suggest that the expression of tumor suppressors and the physical integrity in ME cell layers may have significant predictive value for breast tumor aggressiveness and invasiveness ((Supported in part by grant 2006CB910505 from the Ministry of Chinese Science and Technology Department, and by grants DAMD17‐01‐1‐0129, DAMD1701‐01‐1‐0130, PC051308 from Congressionally Directed Medical Research Programs, and grant BCTR0706983 from The Susan G. Komen Breast Cancer Foundation).